Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold

Benzinga2021-11-26

The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.). The FDA plans to ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Chillman
2021-11-26
Chillman
Ok
- kaite:
  ok
Jen88
2021-11-26
Jen88
Ok
- Chillman:
  Ok
Yappydappy
2021-11-26
Yappydappy
Sian
- Jen88:
  Ok
Never ever f
2021-11-26
Never ever f
Omg
- starry123:
  lol
- Yappydappy:
  Sigh
Cfgramos
2021-11-26
Cfgramos
That’s gonna hurt
- Never ever f:
  Very hurt
LplMichelle
2021-11-26
LplMichelle
Sure

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1136453460?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-26 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136453460","market":"us","top_or_hot":-1,"title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","media":"Benzinga","content":"<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","article_id":"1136453460","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","pubTimestamp":1637933775,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"在关键的新冠肺炎疫苗试验被美国食品和药物管理局搁置后，Ocugen股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":877283354,"gmtCreate":1637935775242,"gmtModify":1637935775393,"author":{"id":"3558275010133966","authorId":"3558275010133966","name":"Chillman","avatar":"https://static.tigerbbs.com/26d692768260a0369516e9c9a49897ec","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877283354","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6736960,"gmtCreate":1637941971493,"gmtModify":1637941971547,"authorId":3583188574218530,"author":{"id":3583188574218530,"authorId":3583188574218530,"name":"kaite","avatar":"https://static.tigerbbs.com/40a7ccc0fdb94090d52b243148991f8a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877283354,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":877289506,"gmtCreate":1637935724761,"gmtModify":1637935729699,"author":{"id":"3582993517958198","authorId":"3582993517958198","name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877289506","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735296,"gmtCreate":1637935782408,"gmtModify":1637935782439,"authorId":3558275010133966,"author":{"id":3558275010133966,"authorId":3558275010133966,"name":"Chillman","avatar":"https://static.tigerbbs.com/26d692768260a0369516e9c9a49897ec","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877289506,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":877289984,"gmtCreate":1637935630854,"gmtModify":1637935631049,"author":{"id":"3579410204959880","authorId":"3579410204959880","name":"Yappydappy","avatar":"https://static.tigerbbs.com/5b6252f503d56d09093797f9e318ebf9","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Sian","listText":"Sian","text":"Sian","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877289984","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735285,"gmtCreate":1637935720387,"gmtModify":1637935720487,"authorId":3582993517958198,"author":{"id":3582993517958198,"authorId":3582993517958198,"name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877289984,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":877212504,"gmtCreate":1637935294425,"gmtModify":1637935294780,"author":{"id":"3555043402922696","authorId":"3555043402922696","name":"Never ever f","avatar":"https://static.tigerbbs.com/52501d43721648c944a019db9c767c5d","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Omg&nbsp;","listText":"Omg&nbsp;","text":"Omg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877212504","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735290,"gmtCreate":1637935761176,"gmtModify":1637935761280,"authorId":3574823700698255,"author":{"id":3574823700698255,"authorId":3574823700698255,"name":"starry123","avatar":"https://static.tigerbbs.com/87d54ddf9f429d363c691c937e6c97a4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877212504,"type":1,"supId":6735269,"prevId":0,"content":"<u>lol</u>","text":"<u>lol</u>","html":"<u>lol</u>"},{"id":6735269,"gmtCreate":1637935622005,"gmtModify":1637935622034,"authorId":3579410204959880,"author":{"id":3579410204959880,"authorId":3579410204959880,"name":"Yappydappy","avatar":"https://static.tigerbbs.com/5b6252f503d56d09093797f9e318ebf9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877212504,"type":1,"supId":0,"prevId":0,"content":"Sigh","text":"Sigh","html":"Sigh"}],"langContent":"CN"},{"id":877218487,"gmtCreate":1637935162172,"gmtModify":1637935162384,"author":{"id":"3577318628836449","authorId":"3577318628836449","name":"Cfgramos","avatar":"https://static.tigerbbs.com/8e4f5dee285970cb0d50c61a4302a33f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"That’s gonna hurt","listText":"That’s gonna hurt","text":"That’s gonna hurt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877218487","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735213,"gmtCreate":1637935302466,"gmtModify":1637935302501,"authorId":3555043402922696,"author":{"id":3555043402922696,"authorId":3555043402922696,"name":"Never ever f","avatar":"https://static.tigerbbs.com/52501d43721648c944a019db9c767c5d","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877218487,"type":1,"supId":0,"prevId":0,"content":"Very hurt ","text":"Very hurt ","html":"Very hurt "}],"langContent":"CN"},{"id":877236626,"gmtCreate":1637934029218,"gmtModify":1637934029431,"author":{"id":"3582025954833628","authorId":"3582025954833628","name":"LplMichelle","avatar":"https://static.tigerbbs.com/f3f2fe5070ffb7507fcc119e4bce015e","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Sure","listText":"Sure","text":"Sure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877236626","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":73,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136453460"}